CytomX Therapeutics, Inc. (CTMX)
3.345
+0.14
(+4.21%)
USD |
NASDAQ |
Aug 31, 16:00
3.345
0.00 (0.00%)
After-Hours: 20:00
CytomX Therapeutics Cash from Investing (Quarterly) : 5.953M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.953M |
| March 31, 2026 | -192.78M |
| December 31, 2025 | -14.42M |
| September 30, 2025 | 0.439M |
| June 30, 2025 | -76.36M |
| March 31, 2025 | 30.60M |
| December 31, 2024 | 15.14M |
| September 30, 2024 | 18.17M |
| June 30, 2024 | 21.51M |
| March 31, 2024 | 44.88M |
| December 31, 2023 | 12.87M |
| September 30, 2023 | -42.94M |
| June 30, 2023 | 26.04M |
| March 31, 2023 | -146.64M |
| December 31, 2022 | 99.82M |
| September 30, 2022 | -0.41M |
| June 30, 2022 | -0.412M |
| March 31, 2022 | -0.736M |
| December 31, 2021 | -0.245M |
| September 30, 2021 | 9.734M |
| June 30, 2021 | -46.01M |
| March 31, 2021 | 59.01M |
| December 31, 2020 | 19.46M |
| Date | Value |
|---|---|
| September 30, 2020 | -90.07M |
| June 30, 2020 | 49.45M |
| March 31, 2020 | 2.441M |
| December 31, 2019 | 52.86M |
| September 30, 2019 | 38.51M |
| June 30, 2019 | 6.94M |
| March 31, 2019 | -18.61M |
| December 31, 2018 | 15.84M |
| September 30, 2018 | -3.18M |
| June 30, 2018 | 16.65M |
| March 31, 2018 | -23.38M |
| December 31, 2017 | -149.76M |
| September 30, 2017 | 15.94M |
| June 30, 2017 | 13.34M |
| March 31, 2017 | -0.788M |
| December 31, 2016 | 42.45M |
| September 30, 2016 | 11.31M |
| June 30, 2016 | -21.48M |
| March 31, 2016 | 13.58M |
| December 31, 2015 | -50.85M |
| September 30, 2015 | 1.297M |
| June 30, 2015 | -28.97M |
| March 31, 2015 | -52.04M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | -92.70M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
| Savara, Inc. | 32.60M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -18.07M |
| Cash from Financing (Quarterly) | 0.511M |
| Free Cash Flow | -82.48M |
| Free Cash Flow Per Share (Quarterly) | -0.0825 |
| Free Cash Flow to Equity (Quarterly) | -20.92M |
| Free Cash Flow to Firm (Quarterly) | -18.07M |
| Free Cash Flow Yield | -13.49% |